- Home
- ANVS vs MAIA Comparison
ANVS vs MAIA Comparison
Compare ANVS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- MAIA
- Stock Information
- Founded
- ANVS 2008
- MAIA 2018
- Country
- ANVS United States
- MAIA United States
- Employees
- ANVS N/A
- MAIA N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- MAIA Health Care
- Exchange
- ANVS Nasdaq
- MAIA Nasdaq
- Market Cap
- ANVS 44.6M
- MAIA 46.7M
- IPO Year
- ANVS 2020
- MAIA 2022
- Fundamental
- Price
- ANVS $2.75
- MAIA $1.88
- Analyst Decision
- ANVS Strong Buy
- MAIA
- Analyst Count
- ANVS 4
- MAIA 0
- Target Price
- ANVS $18.00
- MAIA N/A
- AVG Volume (30 Days)
- ANVS 437.3K
- MAIA 529.1K
- Earning Date
- ANVS 08-14-2025
- MAIA 08-08-2025
- Dividend Yield
- ANVS N/A
- MAIA N/A
- EPS Growth
- ANVS N/A
- MAIA N/A
- EPS
- ANVS N/A
- MAIA N/A
- Revenue
- ANVS N/A
- MAIA N/A
- Revenue This Year
- ANVS N/A
- MAIA N/A
- Revenue Next Year
- ANVS N/A
- MAIA N/A
- P/E Ratio
- ANVS N/A
- MAIA N/A
- Revenue Growth
- ANVS N/A
- MAIA N/A
- 52 Week Low
- ANVS $1.11
- MAIA $1.40
- 52 Week High
- ANVS $14.80
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- ANVS 57.81
- MAIA 56.41
- Support Level
- ANVS $2.24
- MAIA $1.80
- Resistance Level
- ANVS $2.97
- MAIA $2.15
- Average True Range (ATR)
- ANVS 0.26
- MAIA 0.13
- MACD
- ANVS 0.02
- MAIA 0.02
- Stochastic Oscillator
- ANVS 65.58
- MAIA 60.00
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.